February 20, 2024 11:22 AM EST
News Briefing

Io­vance's $211M of­fer­ing; Almi­rall li­cens­es No­vo drug; As­traZeneca files Da­to-DXd; Sonata lay­offs

Ayisha Sharma

News Reporter

Amber Tong

Senior Editor

Lei Lei Wu

News Reporter

Plus oth­er news you may have missed from the FTC, Ever­est, Gilead, IsomAb, Oramed, In­novent, Sonata, Lari­mar and Im­munome.

Io­vance Bio­ther­a­peu­tics of­fers $211M in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times